Immunotherapy for early breast cancer: too soon, too superficial, or just right?
{{output}}
Immunotherapy emerged as a new treatment modality for breast cancer, and its use is approved in combination with chemotherapy for first-line therapy in metastatic triple-negative breast cancer overexpressing PD-L1. As immune checkpoint inhibitors alone have mo... ...
